PDCD1 and squamous cell carcinoma: The clonal repertoire of exhausted CD8+ T cells was largely replaced by novel clones after PD-1 therapy in patients with basal cell carcinoma (BCC) or squamous cell carcinoma (SCC), suggesting the importance of mobilising new, highly clonally expanded specificities that were not present in the pre-treatment tumour [31].